AU2002215277A1 - Improved treatment - Google Patents

Improved treatment

Info

Publication number
AU2002215277A1
AU2002215277A1 AU2002215277A AU1527702A AU2002215277A1 AU 2002215277 A1 AU2002215277 A1 AU 2002215277A1 AU 2002215277 A AU2002215277 A AU 2002215277A AU 1527702 A AU1527702 A AU 1527702A AU 2002215277 A1 AU2002215277 A1 AU 2002215277A1
Authority
AU
Australia
Prior art keywords
iop
prostaglandin
combination
derivative
reducing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002215277A
Other languages
English (en)
Inventor
Teresa Challoner
Donald Gieseker
Anna Gronbladh
Per Jonsson
Patrik Ohagen
Helene Richardson
Thom J. Zimmerman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Health AB
Original Assignee
Pharmacia AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22937766&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002215277(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia AB filed Critical Pharmacia AB
Publication of AU2002215277A1 publication Critical patent/AU2002215277A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Glass Compositions (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
AU2002215277A 2000-11-13 2001-11-12 Improved treatment Abandoned AU2002215277A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24812300P 2000-11-13 2000-11-13
US60/248,123 2000-11-13
PCT/SE2001/002499 WO2002038158A1 (en) 2000-11-13 2001-11-12 Improved treatment

Publications (1)

Publication Number Publication Date
AU2002215277A1 true AU2002215277A1 (en) 2002-05-21

Family

ID=22937766

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002215277A Abandoned AU2002215277A1 (en) 2000-11-13 2001-11-12 Improved treatment

Country Status (17)

Country Link
US (1) US20030018079A1 (no)
EP (1) EP1333837A1 (no)
JP (1) JP2004513148A (no)
KR (1) KR20030068150A (no)
CN (1) CN1233324C (no)
AR (1) AR035541A1 (no)
AU (1) AU2002215277A1 (no)
BR (1) BR0115208A (no)
CA (1) CA2426049A1 (no)
EA (1) EA200300560A1 (no)
HU (1) HUP0400548A3 (no)
MX (1) MXPA03004183A (no)
NO (1) NO20032122L (no)
NZ (1) NZ525817A (no)
PL (1) PL362855A1 (no)
WO (1) WO2002038158A1 (no)
ZA (1) ZA200303771B (no)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI298257B (en) 2001-05-31 2008-07-01 Allergan Inc Hypotensive lipid and timolol compositions and methods of using same
ES2616800T3 (es) * 2002-03-13 2017-06-14 Genomic Health, Inc. Obtención de perfil de expresión génica en tejidos tumorales biopsiados
WO2003079997A2 (en) * 2002-03-21 2003-10-02 Cayman Chemical Company Prostaglandin f2 alpha analogs in combinaiotn with antimicrobials for treating glaucoma
ES2382733T3 (es) 2002-08-29 2012-06-13 Santen Pharmaceutical Co., Ltd. Remedio para el glaucoma que comprende un inhibidor de la Rho quinasa y prostaglandinas
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
JP4314433B2 (ja) 2002-11-18 2009-08-19 参天製薬株式会社 Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
BRPI0414149A (pt) * 2003-09-05 2006-10-31 Novartis Ag composições compreendendo derivados de benzo(g)-quinolina e derivados de prostaglandina
HUE027357T2 (en) 2004-01-05 2016-09-28 Nicox Sa Prostaglandin nitrooxy derivatives
DE602004018990D1 (de) * 2004-05-26 2009-02-26 Bayardo Arturo Jimenez Verfahren zur herstellung einer latanoprost-augenlösung und so hergestellte lösung
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
CN101198354B (zh) 2005-06-21 2012-01-11 兴和株式会社 青光眼的预防或治疗剂
PL1905452T3 (pl) 2005-07-12 2013-11-29 Kowa Co Środek do zapobiegania lub leczenia jaskry
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2010119305A1 (en) * 2009-04-14 2010-10-21 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Using of quaternary ammonium compounds in dissolving of latanoprost
CN102085175B (zh) * 2009-12-02 2013-01-30 沈阳兴齐眼药股份有限公司 一种眼用凝胶剂及其制备方法
FR2961694B1 (fr) * 2010-06-29 2013-01-25 Thea Lab Systeme de delivrance polymerique d'une solution non visqueuse a base de prostaglandine sans conservateur
US9061034B2 (en) 2010-07-29 2015-06-23 Allergan, Inc. Preservative free bimatoprost and timolol solutions
JP6023082B2 (ja) * 2011-01-24 2016-11-09 インセプタム リサーチ アンド セラピューティクス，インク． 精神神経性の疾病を処置するためのプロスタグランジンを含む組成物
TW202126308A (zh) 2011-02-04 2021-07-16 日商興和股份有限公司 青光眼治療劑與高眼壓症治療劑
CN102389433A (zh) * 2011-11-04 2012-03-28 兆科药业(香港)有限公司 一种药物组合物及其复方制剂
CN111491636A (zh) 2017-12-21 2020-08-04 参天制药株式会社 奥米帕格的组合
CA3086457A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Medicament comprising combination of sepetaprost and rho-associated coiled-coil containing protein kinase inhibitor

Also Published As

Publication number Publication date
ZA200303771B (en) 2004-05-17
PL362855A1 (en) 2004-11-02
EP1333837A1 (en) 2003-08-13
KR20030068150A (ko) 2003-08-19
NO20032122D0 (no) 2003-05-12
CN1473046A (zh) 2004-02-04
MXPA03004183A (es) 2004-12-02
EA200300560A1 (ru) 2003-10-30
NO20032122L (no) 2003-07-01
NZ525817A (en) 2005-03-24
HUP0400548A2 (hu) 2004-06-28
CN1233324C (zh) 2005-12-28
WO2002038158A1 (en) 2002-05-16
JP2004513148A (ja) 2004-04-30
WO2002038158A8 (en) 2003-01-30
US20030018079A1 (en) 2003-01-23
BR0115208A (pt) 2003-10-07
AR035541A1 (es) 2004-06-16
CA2426049A1 (en) 2002-05-16
HUP0400548A3 (en) 2007-05-29

Similar Documents

Publication Publication Date Title
AU2002215277A1 (en) Improved treatment
Kerstetter et al. Prostaglandin F2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow
JP4934653B2 (ja) Ｒｈｏキナーゼ阻害剤とβ遮断薬からなる緑内障治療剤
EP1541151B1 (en) REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
JP2019142977A (ja) 緑内障予防又は治療のための薬物療法
JP4482726B2 (ja) Ｒｈｏキナーゼ阻害剤とプロスタグランジン類からなる緑内障治療剤
JP2009102290A (ja) 高眼圧症の治療のための医薬組成物
AU2011282681A1 (en) Preservative free bimatoprost and timolol solutions
Diestelhorst et al. The effect of latanoprost 0.005% once daily versus 0.0015% twice daily on intraocular pressure and aqueous humour protein concentration in glaucoma patients. A randomized, double-masked comparison with timolol 0.5%
US20210346350A1 (en) Methods and compositions for treatment of glaucoma and related conditions
Mochizuki et al. Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects
Lindén Therapeutic potential of prostaglandin analogues in glaucoma
Sit et al. Effects of medications and surgery on intraocular pressure fluctuation
Diestelhorst et al. The additive intraocular pressure-lowering effect of latanoprost 0.005% daily once and pilocarpine 2% tid in patients with open-angle glaucoma or ocular hypertension: a 6-month, randomized, multicenter study
JP2012250951A (ja) アデノシン誘導体とプロスタグランジン類とβ受容体遮断薬の組合せ剤
Miyake et al. Long-term effects of topically applied epinephrine on the blood-ocular barrier in humans
El-Saied et al. Evaluation of topical monotherapy for early primary open angle glaucoma patient
Erdoǧan et al. A short-term study of the additive effect of latanoprost 0.005% and brimonidine 0.2%
Aihara et al. Effects of switching from timolol to brimonidine in prostaglandin analog and timolol combination therapy
US20230372274A1 (en) Compositions and methods for periorbital administration of ep2 receptor agonists
JPH02504150A (ja) 交感神経刺激剤及びベーター１選択性ベータ遮断薬の組合せを含む抗緑内障組成物
JP2024515714A (ja) 散瞳、緑内障、及び他の眼の病態を治療するための方法及び組成物
Mandić et al. Suvremeno liječenje glaukoma otvorenog kuta
Toker et al. A short term study of
RENGARAJ VENKATESH COMMONLY PRESCRIBED GLAUCOMA EYE DROPS AND ORAL MEDICATIONS

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application